Skip to main content

Table 3 Joint effects analysis of combination of Glypican genes in The Cancer Genome Atlas database

From: Prognostic value of Glypican family genes in early-stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy and possible mechanisms

Group No. of events MST (days) Crude HR
95% CI
Crude
P value
Adjusted HR
95% CIa
Adjusted
P valuea
GPC2 + GPC3
 1 21/26(80.8%) 278 1 0.001 1 < 0.001
 2 37/60(61.7%) 568 0.441(0.252–0.772) 0.004 0.350(0.187–0.653) 0.001
 3 11/26(42.3%) 702 0.285(0.135–0.598) 0.001 0.173(0.072–0.418) < 0.001
GPC2 + GPC5
 I 18/23(78.3%) 278 1 0.001 1 < 0.001
 II 40/66(60.6%) 517 0.424(0.237–0.758) 0.004 0.283(0.145–0.554) < 0.001
 III 11/23(47.8%) 702 0.253(0.116–0.552) 0.001 0.141(0.057–0.353) < 0.001
GPC3 + GPC5
 i 26/38(68.4%) 393 1 0.028 1 0.018
 ii 21/36(58.3%) 498 0.685(0.383–1.226) 0.203 0.575(0292–1.129) 0.108
 iii 22/38(57.9%) 691 0.443(0.243–0.805) 0.008 0.394(0.206–0.756) 0.005
GPC2 + GPC3 + GPC5
 A 13/16(81.2%) 219 1 0.028 1 < 0.001
 B 26/39(66.7%) 517 0.494(0.250–0.974) 0.042 0.446(0.212–0.938) 0.033
 C 23/42(54.8%) 592 0.269(0.130–0.560) < 0.001 0.176(0.076–0.406) < 0.001
 D 7/15(46.7%) 702 0.204(0.079–0.526) 0.001 0.135(0.045–0.403) < 0.001
  1. Group 1:low GPC2 + low GPC3; Group 2:low GPC2 + high GPC3 or high GPC2+ low GPC3; Group 3: high GPC2 + high GPC3
  2. Group I:low GPC2 + low GPC5; Group II:low GPC2 + high GPC5 or high GPC2 + low GPC5; Group III: high GPC2 + high GPC5
  3. Group i:low GPC3 + low GPC5; Group ii:low GPC3 + high GPC5 or high GPC3 + low GPC5; Group iii: high GPC3 + high GPC5
  4. Group A:low GPC2 + low GPC3 + low GPC5; Group B: high GPC2 + low GPC3 + low GPC5 or low GPC2 + high GPC3 + low GPC5 or low GPC2 + low GPC3 + high GPC5; Group C:high GPC2 + high GPC3 + low GPC5 or high GPC2 + low GPC3 + high GPC5 or low GPC2 + high GPC3 + high GPC5; Group D:high GPC2 + high GPC3 + high GPC5
  5. Abbreviations: MST median survival time, HR hazard ratio, CI confidence interval
  6. aAdjusted for histologic grade, targeted molecular therapy, radiation therapy and radical resection